 DUBLIN, March 8, 2022 PRNewswire -- Jazz Pharmaceuticals plc Nasdaq: JAZZ today announced that pre-clinical data on JZP815, an investigational, next-generation pan-RAF kinase inhibitor, will be presented as a poster at the American Association for Cancer Research AACR 2022 Annual Meeting from April 8-13, 2022. Together with our pre-clinical collaboration partner, Redx Pharma, we look forward to presenting at AACR our first pre-clinical data on JZP815, which demonstrated that it selectively and potently inhibits mutant A, B and CRAF kinases, and demonstrated anti-tumor activity in RAS- and RAF-mutant xenograft models, said Rob Iannone, M.D. 